title: Metabolic effects of silibinin in the rat liver.
abstract: The flavonolignan silibinin, which is a mixture of two diastereoisomers, silybin A and silybin B, is a component of the extract obtained from the fruit and seeds of the variegated milk thistle (Silybum marianum (L.) Gaertn. (Asteraceae)), known as silymarin. Among the therapeutic properties credited to silibinin, its antihyperglycaemic action has been extensively explored. Silibinin is structurally related to the flavonoids quercetin and fisetin, which have been previously demonstrated to be very active on liver metabolic processes related to glycaemic regulation. The aim of the present work was to investigate the effects of silibinin on metabolic pathways responsible for the maintenance of glycaemia, particularly glycogenolysis and gluconeogenesis, in the perfused rat liver. The activities of some key enzymes in these pathways and on parameters of energy metabolism in isolated mitochondria were also examined. At a concentration range of 50-300μM, silibinin inhibited gluconeogenesis in the fasted condition and inhibited glycogenolysis and glycolysis in the fed condition. The mechanisms by which silibinin exerted these actions were multiple and complex. It inhibited the activity of glucose 6-phosphatase, inhibited the pyruvate carrier, and reduced the efficiency of mitochondrial energy transduction. It can also act by reducing the supply of NADH for gluconeogenesis and mitochondria through its pro-oxidative actions. In general, the effects and the potency of silibinin were similar to those of quercetin and fisetin. However, silibinin exerted some distinct effects such as the inhibitory effect on oxygen consumption in the fed condition and a change in the energy status of the perfused livers. It can be concluded that the effects of silibinin on liver glucose metabolism may explain its antihyperglycaemic property. However, this effect was, in part, secondary to impairment in cellular energy metabolism, a finding that should be considered in its therapeutic usage.
authors.affiliation: Department of Biochemistry, Laboratory of Liver Metabolism, University of Maringá, Paraná, Brazil. carina_colturato@yahoo.com.br
authors.forename: Carina Parisoto
authors.initials: CP
authors.lastname: Colturato
authors.forename: Rodrigo Polimeni
authors.initials: RP
authors.lastname: Constantin
authors.forename: Antônio Sueiti
authors.initials: AS
authors.lastname: Maeda
authors.forename: Renato Polimeni
authors.initials: RP
authors.lastname: Constantin
authors.forename: Nair Seiko
authors.initials: NS
authors.lastname: Yamamoto
authors.forename: Adelar
authors.initials: A
authors.lastname: Bracht
authors.forename: Emy Luiza
authors.initials: EL
authors.lastname: Ishii-Iwamoto
authors.forename: Jorgete
authors.initials: J
authors.lastname: Constantin
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D001786:Blood Glucose / Q000378:metabolism; D044947:Flavonolignans / Q000378:metabolism; D005943:Gluconeogenesis / Q000187:drug effects; D006019:Glycolysis / Q000187:drug effects; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D008297:Male; D008659:Metabolic Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008930:Mitochondria, Liver / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D010101:Oxygen Consumption / Q000187:drug effects; D011766:Pyruvate Carboxylase / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D000077385:Silybin; D012838:Silymarin / Q000494:pharmacology*
chemical_list: D000975:Antioxidants; D001786:Blood Glucose; D044947:Flavonolignans; D007004:Hypoglycemic Agents; D012838:Silymarin; D000077385:Silybin; D011766:Pyruvate Carboxylase